These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 15692268)
61. Ways of escape: are all tumours angiogenic? Pezzella F; Harris AL; Gatter KC Histopathology; 2001 Dec; 39(6):551-3. PubMed ID: 11903570 [No Abstract] [Full Text] [Related]
62. Clinical significance of cancer cells in the circulating blood: two- to five-year survival. ROBERTS S; JONASSON O LONG L; McGRATH R; McGREW EA; COLE WH Ann Surg; 1961 Sep; 154(3):362-71. PubMed ID: 13742183 [No Abstract] [Full Text] [Related]
63. Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Ilie M; Long E; Hofman V; Selva E; Bonnetaud C; Boyer J; Vénissac N; Sanfiorenzo C; Ferrua B; Marquette CH; Mouroux J; Hofman P Br J Cancer; 2014 Mar; 110(5):1236-43. PubMed ID: 24473396 [TBL] [Abstract][Full Text] [Related]
64. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Rabascio C; Muratori E; Mancuso P; Calleri A; Raia V; Foutz T; Cinieri S; Veronesi G; Pruneri G; Lampertico P; Iavarone M; Martinelli G; Goldhirsch A; Bertolini F Cancer Res; 2004 Jun; 64(12):4373-7. PubMed ID: 15205354 [TBL] [Abstract][Full Text] [Related]
65. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Taylor M; Rössler J; Geoerger B; Laplanche A; Hartmann O; Vassal G; Farace F Clin Cancer Res; 2009 Jul; 15(14):4561-71. PubMed ID: 19605404 [TBL] [Abstract][Full Text] [Related]
66. Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology. Bertolini F Breast; 2009 Oct; 18 Suppl 3():S48-50. PubMed ID: 19914542 [TBL] [Abstract][Full Text] [Related]
67. Strategies to investigate circulating endothelial cells in cancer. Mancuso P; Rabascio C; Bertolini F Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):503-6. PubMed ID: 15692268 [TBL] [Abstract][Full Text] [Related]
68. Circulating endothelial cells and circulating endothelial progenitors. Mancuso P; Calleri A; Bertolini F Recent Results Cancer Res; 2012; 195():163-70. PubMed ID: 22527503 [TBL] [Abstract][Full Text] [Related]
69. Circulating endothelial cells as biomarkers in clinical oncology. Mancuso P; Bertolini F Microvasc Res; 2010 May; 79(3):224-8. PubMed ID: 20176038 [TBL] [Abstract][Full Text] [Related]
70. Clinical value of circulating endothelial cell detection in oncology. Kraan J; Sleijfer S; Foekens JA; Gratama JW Drug Discov Today; 2012 Jul; 17(13-14):710-7. PubMed ID: 22306349 [TBL] [Abstract][Full Text] [Related]
71. [Circulating endothelial cells: biomarkers for monitoring activity of antiangiogenic therapy]. Farace F; Bidart JM Bull Cancer; 2007 Jul; 94 Spec No():S254-9. PubMed ID: 17846012 [TBL] [Abstract][Full Text] [Related]
72. Angiogenesis: a curse or cure? Gupta K; Zhang J Postgrad Med J; 2005 Apr; 81(954):236-42. PubMed ID: 15811887 [TBL] [Abstract][Full Text] [Related]
73. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893 [TBL] [Abstract][Full Text] [Related]